文献速递妇科

CXCL10改变同基因小鼠高级别浆液性卵巢癌模型的肿瘤免疫微环境与疾病进展

CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2017-03-17

在同基因ID8小鼠高级别浆液性卵巢癌模型中,过表达CXCL10可减少肿瘤负荷与腹水,降低腹水IL-6和VEGF水平,减少肿瘤血管与增殖;敲低CXCL10则增加腹水与疾病进展。CXCL10是抗肿瘤免疫反应与疾病进展的正向决定因素。

要点

  • ID8同基因小鼠模型中,过表达CXCL10减少肿瘤负荷和恶性腹水。
  • 过表达CXCL10组腹水IL-6与VEGF水平较对照显著降低。
  • 敲低CXCL10增加腹水积累并促进疾病进展。

核心结论

  • CXCL10是高级别浆液性卵巢癌肿瘤免疫微环境中抗肿瘤免疫反应与疾病进展的正向决定因素。
  • 这些发现为未来通过利用肿瘤免疫微环境改善治疗反应和生存的转化研究奠定基础。

研究设计与样本

  • 研究采用ID8同基因小鼠高级别浆液性卵巢癌模型。
  • 构建CXCL10稳定敲低和过表达的ID8卵巢癌细胞系及其载体对照,经腹腔注射植入免疫健全C57BL/6小鼠。
  • 终点进行肿瘤组织免疫转录组分析和腹水多重细胞因子检测,并用CD31和Ki67免疫染色评估肿瘤血管和细胞增殖。

主要发现

  • 过表达CXCL10导致ID8同基因小鼠模型肿瘤负荷和恶性腹水积累减少。
  • 过表达CXCL10小鼠腹水IL-6和VEGF水平较载体对照显著降低。
  • 过表达CXCL10肿瘤的血管密度(CD31)和增殖指数(Ki67)较对照肿瘤降低。
  • 过表达CXCL10肿瘤中抗原加工、凋亡和T细胞功能相关基因表达较对照显著升高。
  • 敲低CXCL10肿瘤较对照导致腹水积累增加和疾病进展。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We recently established that high STAT1 expression and associated T helper type I tumour immune microenvironment (TME) are prognostic and chemotherapy response predictive biomarkers in high-grade serous ovarian cancer (HGSC). STAT1 induced chemokine CXCL10 is key to the recruitment of lymphocytes in the TME and is significantly highly expressed in the tumours from patients with longer survival. In the current study we therefore aimed to elucidate the role CXCL10 in disease progression and tumour immune transcriptomic alterations using the ID8 syngeneic murine model of HGSC. METHODS: ID8 ovarian cancer cells were engineered for stable knockdown (KD) and overexpression (OX) of CXCL10. The OX and KD cell line derivatives, along with their respective vector controls, were implanted in immunocompetent C57BL/6 mice via intra-peritoneal injections. At end point, immune transcriptomic profiling of tumour tissues and multiplex cytokine profiling of ascites, was performed. Effect of CXCL10 expression on the tumour vasculature and tumour cell proliferation was evaluated by CD31 and Ki67 immunostaining, respectively. RESULTS: Increased CXCL10 expression led to decreased tumour burden and malignant ascites accumulation in the ID8 syngeneic murine model of HGSC. The ascites levels of IL-6 and VEGF were significantly reduced in OX mice compared to the vector controls. The OX tumours also showed reduced vasculature (CD31) and proliferative index (Ki67) compared to the control tumours. Significantly higher expression of genes associated with antigen processing, apoptosis and T cell function was observed in OX tumours compared to the controls. Reduced CXCL10 expression in tumours from KD mice led to increased ascites accumulation and disease progression compared to the controls. CONCLUSION: CXCL10 is a positive determinant of anti-tumour immune responses in HGSC TME and disease progression. These findings are foundational for future translational studies aimed at improving treatment response and survival in HGSC patients, via exploiting the TME.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. K Au K, Peterson N, Truesdell P, et al. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer. Gynecol Oncol. 2017. PMID: 28318643. doi:10.1016/j.ygyno.2017.03.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。